The need for standardization of methods for laboratory control of anticoagulant therapy is well established (Poller, 1964 (Poller, , 1967 Biggs and Denson, 1967; Miale and La Fond, 1967) . The emphasis in this country has been on the provision of a thromboplastin standard with lyophilized plasma playing a secondary part (Poller, 1967) , whereas Miale and La Fond (1967) used freeze-dried plasma standards in a large prothrombin-time test survey in the United States.
The need for standardization of methods for laboratory control of anticoagulant therapy is well established (Poller, 1964 (Poller, , 1967 Biggs and Denson, 1967; Miale and La Fond, 1967) . The emphasis in this country has been on the provision of a thromboplastin standard with lyophilized plasma playing a secondary part (Poller, 1967) , whereas Miale and La Fond (1967) used freeze-dried plasma standards in a large prothrombin-time test survey in the United States.
It therefore seemed important to determine the reliability of the use of dried plasma standards at individual hospitals. By the provision, in addition, of standard thromboplastin extract (Manchester Comparative Reagent) it has been possible to observe how plasma results varied even though identical laboratory reagents were used at the different hospitals.
Method of Study
Of the 142 major hospital centres that participated in our previous national survey (Poller and Thomson, 1968) 66 were invited to take part in this additional study. This was not an arbitrary selection, but was guided by our desire to include an equal proportion of hospitals using human brain reagents and commercial animal tissue extracts. Hospitals participating in our routine supply scheme were of course excluded, as they do not use other thromboplastin extracts.
The following were sent to each of the hospitals: (1) a fresh supply of Manchester Comparative Reagent human brain thromboplastin-this is a phenolized liquid preparation; and (2) two ampoules of lyophilized coumarin plasma-one from a patient with a marked depression of all four clotting factors, and one from a severe pure factor VII deficiency-these samples being from single donors treated with nicoumalone (Sinthrome). The criteria for factor VII deficiency were as follows: (1) gross prolongation of the prothrombin time, (2) normal " intrinsic " system assessed by assay, (3) normal factor X level, and (4) restoration of prothrombin time by dilute stored serum.
The hospitals were asked to give details of their own reagent. They were asked to carry out parallel tests with their own thromboplastin and the Manchester standard on two fresh normal control plasmas. Then they were to perform duplicate tests on the two lyophilized plasmas, using both their own tissue extract and the standard. They were also asked to perform the test within seven days of receipt of the reagents so that their possible deterioration should not influence results.
The plasma specimens were tested by us before dispatch, again on the day of dispatch, and also at the end of the period of study. Plasma Normal Controls.-The distribution of prothrombin times (in seconds) for the normal controls used in the different hospitals is shown in Fig. 1 . The distribution of the prothrombin times with the Manchester standard, the " home-made " human brains, and the commercial reagents is given. plasma 1 are plotted as ratios in Fig. 2 , which gives the distribution at the various hospitals using the Manchester standard,
human brains, and commercial extracts. Fig. 3 gives the results obtained with the pure factorViI-deficient specimen (plasma 2) in a similar way. Thromboplastin standard is also necessary to determine the " equivalent " prothrombin ratio (Biggs and Denson, 1967) which returned results in the present survey could be studied, because in the meantime the others had changed their thromboplastin preparations. We compared the scatter of the equivalent ratios based on a thromboplastin standard with the scatter of ratios at the same hospitals using the single dried coumarin plasma, deficient in all four clotting factors.
In Fig. 4 the distribution of values for the prothrombin ratio equivalent to 1.7 with the standard Manchester reagent is given as well as the distribution of individual plasma ratios at the different hospitals. Fig. 5 gives the similar distributions for the commercial extracts.
Discussion
This study differs in many respects from the survey conducted in the United States by Miale and La Fond (1967) .
Though far fewer hospitals have been included in our investigation more data are available from each centre, as in addition to the provision of standard plasma we have provided standard thromboplastin reagent together with a recommended uniform technique for parallel studies with their own reagents at the different hospitals.
The distribution of results obtained from the fresh normal control plasma by the use of the Manchester standard thromboplastin is a reasonable one. Only a small number of results fell outside the normal range we have established at our own laboratory. The normal results with the other human brain preparations and commercial animal reagents were not so close. The variation in the normal values was taken into account, as the results of dried plasma 1 and 2 were expressed as a ratio of the normal result in seconds at each hospital.
There was more reproducibility with the Manchester standard than with the individual home-made human brain extracts and also than with the commercial extracts with both the dried plasma specimens. The Manchester reagent and the home-made human brain reagents were also more sensitive to the coumarin defect than the commercial extracts with both dried plasma specimens. This parallels the result in the previous survey, where none of the commercial reagents gave as good prothrombin ratios as the human brain preparations-that is, animal preparations were less sensitive to the coumarin defect (Poller and Thomson, 1968) .
The ability of a single dried plasma standard to characterize an unknown tissue thromboplastin is seen to be very poor when contrasted with the provision of a standard sensitive thromboplastin-for example, human brain-for parallel studies. Figs. 4 and 5 show the very good agreement at different centres where the equivalent prothrombin ratio was determined by parallel observation on groups of 20 fresh coumarin plasma samples. They also show the wide distribution and lack of agreement between the prothrombin ratios obtained from dried coumarin plasma at the same hospitals. Apart from assessing the sensitivity of a thromboplastin to the depression of individual coagulation factors by using deficient plasma, results obtained from a single dried plasma standard appear relatively valueless owing to uncontrolled variations in laboratory technique.
With use of the same reagent based on the technique with the Manchester standard prothrombin ratios on the same plasma varied between 2.7 and 7.6 with plasma 1 and 2.7 and 11.5 with plasma 2. With different home-made thromboplastin the distribution was even greater. The scatter was not so great with commercial extracts, but these were uniformly insensitive to the coumarin defect (see Fig. 5 ).
All the many variables which affect prothrombin time results in seconds affect the readings with dried plasma, and these are From this survey it appears that the place of a dried plasma standard should be limited to that of a useful adjunct to standard thromboplastin in the provision of a uniform service for laboratory control of anticoagulants (see Table) . Where a suitable sensitive human brain standard is available it is doubtful if standard dried plasma provides much additional information. It might be possible at some future date to improve the poor performance of plasma standards by greater attention to the many variables, but a lot more work is required before this becomes a practical proposition.
Summaiy
A study has been carried out to determine the reliability of the use of dried plasma standards at individual hospitals. By the provision, in addition, of standard thromboplastin extract (Manchester Comparative Reagent) it has been possible to observe how plasma results varied even though identical laboratory reagents were used at the different hospitals.
The following were sent: (1) a fresh supply of Manchester Comparative Reagent human brain thromboplastin, and (2) two ampoules of lyophilized coumarin plasma-one from a patient with a marked depression of all four clotting factors, and one from a severe pure factor VII deficiency. Results were returned from 58 hospital centres. The ability of a single dried plasma standard to characterize an unknown tissue thromboplastin was seen to be very poor when contrasted with the provision of a standard sensitive thromboplastin. It appears that the place of a dried plasma standard should be limited to that of a useful adjunct to standard thromboplastin in the provision of a uniform service for laboratory control of anticoagulants. Where a suitable sensitive human brain standard is available it is doubtful if standard dried plasma provides much additional information. It might be possible at some future date to improve the poor performance of plasma standards, but a lot more work is required.
We are indebted to our many pathologist and haematologist colleagues who participated in this further survey. Without their willing help and co-operation the study would not have been possible. The study was performed while in receipt of a grant for thrombosis research from the Manchester Regional Board.
